Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/TORNTPHARM stock hub

NSE/TORNTPHARM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/TORNTPHARMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.5T

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/TORNTPHARM

In the news

Latest news · NSE/TORNTPHARM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E64.1

P25 24.9P50 32.4P75 45.7

Trailing P/E65.2

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC24.2

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/TORNTPHARM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

199

Groups with data

Currency

INR

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	17,059
Employees Change	1,341%
Employees Change Percent	8.53
Enterprise value	INR 1.5T
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE685A01028
Last refreshed	2026-05-10
Market cap	INR 1.5T
Price	INR 4,379
Price currency	INR
Rev Per Employee	7,469,423.76x
Sector	Healthcare
Sic	2834
Symbol	nse/TORNTPHARM
Website	https://www.torrentpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.53%
EV Earnings	66.14x
EV/EBIT	44.79x
EV/EBITDA	36.41x
EV/Sales	11.79x
Forward P/E	64.11x
P/B ratio	17.55x
P/E ratio	65.24x
P/S ratio	11.63x
PE Ratio10 Y	44.72x
PE Ratio3 Y	54.58x
PE Ratio5 Y	53.27x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	26.33%
EBITDA Margin	32.2%
Gross margin	75.64%
Gross Profit	INR 96.4B
Gross Profit Growth	12.36%
Gross Profit Growth Q	17.23%
Gross Profit Growth3 Y	13.42%
Gross Profit Growth5 Y	10.56%
Net Income	INR 22.7B
Net Income Growth	22.01%
Net Income Growth Q	26.24%
Net Income Growth Quarters	13%
Net Income Growth Years	3%
Net Income Growth3 Y	39.83%
Net Income Growth5 Y	12.85%
Pretax Margin	23.61%
Profit Margin	17.83%
Profit Per Employee	INR 1.3M
Profitable Years	21
Roa5y	9.73
Roe5y	21.8
ROIC	24.19
Roic5y	15.78

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	21.61%
Cagr15y	26.97%
Cagr1y	34.23%
Cagr20y	25.45%
Cagr3y	39.89%
Cagr5y	28.96%
Div CAGR10	10.31%
Div CAGR3	11.13%
Div CAGR5	28.47%
EPS Growth	21.97
EPS Growth Q	26.14
EPS Growth Quarters	13
EPS Growth Years	3
EPS Growth3 Y	39.85
EPS Growth5 Y	12.84
Revenue Growth	12.74x
Revenue Growth Q	17.59x
Revenue Growth Quarters	24x
Revenue Growth Years	8x
Revenue Growth3 Y	11.23x
Revenue Growth5 Y	9.72x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 7.9B
Debt	INR 28.2B
Debt EBITDA	INR 0.68
Debt Equity	INR 0.33
Equity	INR 84.5B
Interest Coverage	16.42
Net Cash	INR -20.3B
Net Cash By Market Cap	INR -1.37
Net Debt EBITDA	INR 0.49
Net Debt Equity	INR 0.24
Tangible Book Value	INR 40.7B
Tangible Book Value Per Share	INR 120
WACC	5.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.03%
Dividend Growth	9.38%
Dividend Growth Years	2%
Dividend per share	INR 35
Dividend Years	24
Dividend Yield	0.8%
Ex Div Date	2026-02-18
Last Dividend	INR 29
Payout Frequency	Semi-Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	607.18%
1Y total return	34.21%
200-day SMA	3,863.7
3Y total return	173.82%
50-day SMA	4,247.7
50-day SMA vs 200-day SMA	50over200
5Y total return	256.56%
All Time High	4,482.9
All Time High Change	-2.33%
All Time High Date	2026-03-13
All Time Low	9.69
All Time Low Change	45,095.09%
All Time Low Date	2003-04-28
ATR	94.44
Beta	0.15
Ch YTD	13.73
High	4,398.4
High52	4,482.9
High52 Date	2026-03-13
High52ch	-2.33%
Low	4,336.7
Low52	3,101.6
Low52 Date	2025-05-09
Low52ch	41.17%
Ma50ch	3.08%
Price vs 200-day SMA	13.32%
RSI	63.8
RSI Monthly	73.75
RSI Weekly	67.27
Sharpe ratio	1.44x
Sortino ratio	2.73
Total Return	0.77%
Tr YTD	14.51
Tr15y	3,494.85%
Tr1m	8.08%
Tr1w	2.98%
Tr3m	11.92%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 33.6B
Operating Income Growth	17.5
Operating Income Growth Q	23.36
Operating Income Growth3 Y	18.85
Operating Income Growth5 Y	13.35
Operating margin	26.33

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	103,982,880%
Shares Insiders	0.28%
Shares Institutions	17.44%
Shares Qo Q	-0.11%
Shares Yo Y	0.03%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	325,784.45x
Bv Per Share	249.5
Ch10y	528.6
Ch15y	2,758
Ch1m	8.08
Ch1w	2.98
Ch1y	33.04
Ch20y	6,730.7
Ch3m	11.16
Ch3y	165.4
Ch5y	234.7
Ch6m	22.3
Change	0.36%
Change From Open	0.66
Close	4,362.7
Days Gap	-0.29
Depreciation Amortization	7,476,675,000
Dollar Volume	511,443,828
Earnings Date	2026-05-22
EBIT	INR 33.6B
EBITDA	INR 41B
EPS	INR 67.12
F Score	1
Fiscal Year End	March
Founded	1,959
Graham Number	613.83245
Graham Upside	-85.98
Income Tax	INR 7.4B
Is Primary Listing	0
Last Earnings Date	2026-01-23
Last Report Date	2025-12-31
Last Split Date	2022-07-08
Last Split Type	Forward
Lynch Fair Value	INR 862
Lynch Upside	-80.31
Ma150	3,951.3
Ma150ch	10.81%
Ma20	4,202.5
Ma20ch	4.19%
Next Earnings Date	2026-05-22
Open	4,350
Payment Date	2026-03-15
Position In Range	67.75
Price Date	2026-05-08
Price EBITDA	INR 36.13
Ptbv Ratio	36.46
Relative Volume	0.34x
Revenue	127,420,900,000x
Tax By Revenue	5.77x
Tax Rate	24.46%
Tr20y	9,224.48%
Tr6m	23.14%
Volume	116,808

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/TORNTPHARM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.8%

$35.0 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+28.5%

2 consecutive years of growth

Total shareholder yield

+0.8%

Next ex-dividend date: 2026-02-18

Performance

NSE/TORNTPHARM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/TORNTPHARM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.4%

Share of float held by funds and institutions

Insider ownership

+0.3%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.0%

Negative means the company is buying back shares.

Technical

NSE/TORNTPHARM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

63.8

Neutral momentum band

Price vs 200-day MA

+13.3%

50/200-day relationship not available

Beta (5Y)

0.14

Less volatile than the market

Sharpe ratio

1.44

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/TORNTPHARM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/TORNTPHARM stock rating?

nse/TORNTPHARM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/TORNTPHARM analysis?

The full report lives at /stocks/nse/TORNTPHARM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/TORNTPHARM?

The latest report frames nse/TORNTPHARM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/TORNTPHARM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.